import { Tutorial } from '../types/tutorial';

export const amrDetectionMasterclass: Tutorial = {
  id: 'amr-detection-masterclass',
  slug: 'amr-detection-masterclass',
  title: 'AMR Detection Masterclass: Finding Resistance Genes',
  description: 'Master antimicrobial resistance (AMR) gene detection using Abricate, AMRFinderPlus, and ResFinder. Learn to identify ESBL, carbapenemase, and other resistance mechanisms threatening global health.',
  category: 'intermediate',
  difficulty: 'intermediate',
  duration: 120,
  xpReward: 300,
  tags: ['AMR', 'Antibiotic Resistance', 'ESBL', 'Carbapenemase', 'Public Health', 'WHO Priority'],
  author: 'BioNXA Team',
  prerequisites: [
    'intro-to-bioinformatics',
    'genomic-characterization-upec',
    'Understanding of bacterial genetics'
  ],
  learningObjectives: [
    'Understand mechanisms of antibiotic resistance',
    'Detect resistance genes using Abricate and AMRFinderPlus',
    'Interpret WHO priority pathogen classifications',
    'Identify ESBL, carbapenemase, and plasmid-mediated resistance',
    'Connect genotype to phenotype (gene to resistance)',
    'Understand clinical implications for treatment',
    'Perform comparative AMR analysis across isolates'
  ],
  sections: [
    {
      id: 'amr-intro',
      title: '1. The Global AMR Crisis',
      type: 'text',
      content: `# Antimicrobial Resistance: A Global Emergency

## The Silent Pandemic

While COVID-19 dominated headlines, another pandemic has been silently killing:

### üî¥ AMR by the Numbers (2019 Data)

- **4.95 million deaths** associated with AMR
- **1.27 million deaths** directly caused by AMR
- **More deaths than HIV or malaria**
- **$100 billion** annual global healthcare costs
- **10 million projected deaths by 2050** if unchecked

Source: Lancet 2022 - Global burden of bacterial AMR

## What is Antimicrobial Resistance?

**AMR** occurs when bacteria evolve mechanisms to survive antibiotic exposure:

\`\`\`
Normal Bacteria ‚Üí Antibiotic Exposure ‚Üí Selection Pressure ‚Üí Resistant Mutant ‚Üí Population Shift
\`\`\`

### The Perfect Storm

Three factors accelerate AMR:

1. **Overuse** - Unnecessary prescriptions (50% inappropriate)
2. **Misuse** - Wrong antibiotic, wrong dose, incomplete course
3. **Agricultural Use** - 80% of antibiotics used in livestock

## Mechanisms of Resistance

### 1. Œ≤-Lactamases (Enzyme Production)

**Destroy the antibiotic before it acts**

\`\`\`
Penicillin ‚Üí Œ≤-lactamase ‚Üí Inactive Product
    ‚Üì
 Œ≤-lactam ring broken
\`\`\`

**Major families**:
- **ESBLs** (Extended-Spectrum Œ≤-Lactamases) - CTX-M, TEM, SHV
- **AmpC** - Chromosomal and plasmid types
- **Carbapenemases** - KPC, NDM, OXA-48, VIM

### 2. Target Modification

**Change the drug target so it no longer binds**

**Examples**:
- **gyrA/parC** mutations ‚Üí Fluoroquinolone resistance
- **rpoB** mutations ‚Üí Rifampin resistance
- **PBP** alterations ‚Üí Methicillin resistance (MRSA)

### 3. Efflux Pumps

**Pump the antibiotic out of the cell**

\`\`\`
Antibiotic enters ‚Üí Efflux pump activates ‚Üí Antibiotic expelled
       ‚Üì                                            ‚Üë
Internal concentration too low to kill
\`\`\`

**Example**: *acrAB-tolC* system (fluoroquinolones, tetracyclines)

### 4. Decreased Permeability

**Prevent antibiotic from entering the cell**

**Mechanisms**:
- Loss of porins (OmpF, OmpC)
- Membrane modifications
- Biofilm formation

### 5. Alternative Pathways

**Bypass the inhibited target**

**Example**: Sulfonamide resistance
- Bacteria acquire alternative DHPS enzyme
- Bypasses sulfonamide-inhibited pathway

## The WHO Priority Pathogens List

### Critical Priority (Urgent Need for New Antibiotics)

1. **Carbapenem-resistant *Acinetobacter baumannii***
2. **Carbapenem-resistant *Pseudomonas aeruginosa***  
3. **Carbapenem-resistant, ESBL-producing *Enterobacterales***
   - ‚ö†Ô∏è **Our focus: ESBL *E. coli* (UPEC)**

### High Priority

- Vancomycin-resistant *Enterococcus faecium*
- MRSA (*Staphylococcus aureus*)
- Fluoroquinolone-resistant *Salmonella*
- Fluoroquinolone-resistant *Neisseria gonorrhoeae*

### Medium Priority

- Macrolide-resistant *Streptococcus pneumoniae*
- Others

## ESBL-Producing *E. coli*: Our Case Study

### What are ESBLs?

**Extended-Spectrum Œ≤-Lactamases** hydrolyze:
- ‚úÖ Penicillins (ampicillin, piperacillin)
- ‚úÖ 3rd-generation cephalosporins (ceftriaxone, cefotaxime, ceftazidime)
- ‚úÖ 4th-generation cephalosporins (cefepime)
- ‚ùå NOT carbapenems (meropenem, ertapenem) - still effective

### Most Common ESBLs in *E. coli*

#### 1. CTX-M Family

**blaCTX-M-15** - Most widespread globally
- Found in ST131 pandemic clone
- Preferentially hydrolyzes cefotaxime (CTX)
- Often on IncF plasmids (easily transferred)
- Associated with fluoroquinolone resistance

**blaCTX-M-27** - Emerging threat
- Found in ST131 fimH30 subclone
- Higher expression level
- Spreading rapidly in Asia and Europe

#### 2. SHV Family

**blaSHV-12** - Common in hospitals
- Derived from blaSHV-1 by mutation
- Often chromosomal in *Klebsiella*
- Plasmid-borne in *E. coli*

#### 3. TEM Family

**blaTEM-52** - Highly resistant
- Evolved from blaTEM-1
- Multiple mutations increase spectrum
- Resistant to some Œ≤-lactamase inhibitors

### Clinical Impact of ESBL-Producing UPEC

**Complications**:
- ‚ùå Treatment failures with cephalosporins
- ‚ö†Ô∏è Bacteremia (bloodstream infection) - 30% mortality
- üè• Longer hospital stays (average +6 days)
- üí∞ Higher costs ($10,000+ per case)
- üîÅ Recurrent infections

**Limited Treatment Options**:
- Carbapenems (meropenem, ertapenem)
- Nitrofurantoin (UTI only)
- Fosfomycin (UTI only)
- Amikacin (severe infections)
- Tigecycline (alternative)

### Co-Resistance: The Real Danger

ESBL genes rarely travel alone:

\`\`\`
Plasmid carrying:
‚îú‚îÄ‚îÄ blaCTX-M-15 (ESBL)
‚îú‚îÄ‚îÄ aac(6')-Ib-cr (aminoglycoside + quinolone)
‚îú‚îÄ‚îÄ qnrB (fluoroquinolone)
‚îú‚îÄ‚îÄ sul1/2 (sulfonamide)
‚îú‚îÄ‚îÄ tet(A) (tetracycline)
‚îî‚îÄ‚îÄ dfrA (trimethoprim)

Result: Multidrug-resistant "superbug"
\`\`\`

### Our Dataset: What to Expect

Based on Aljohani et al. 2023 study:

**Resistance Genes Found**:
- **blaCTX-M-15** - 40% of isolates
- **blaCTX-M-27** - 15% of isolates
- **aac(6')-Ib-cr** - 60% (aminoglycoside/quinolone resistance)
- **qnrB, qnrS** - 45% (fluoroquinolone resistance)
- **sul1, sul2** - 70% (sulfonamide resistance)
- **tet(A), tet(B)** - 55% (tetracycline resistance)
- **dfrA** - 50% (trimethoprim resistance)

**Association with ST131**:
- 18/18 ST131 isolates carry ESBL
- Most have blaCTX-M-15
- All fluoroquinolone-resistant
- Median 6 resistance genes per isolate

## Why Genomic Surveillance Matters

### Traditional AST vs. Genomic AMR Detection

| Aspect | AST (Disk Diffusion) | Genomic Detection |
|--------|---------------------|-------------------|
| **Speed** | 18-24 hours | 8-12 hours |
| **Mechanism** | Unknown | Identified |
| **Transmission** | No info | Identifies outbreaks |
| **Prediction** | Current | Predicts future |
| **Cost** | $10-20 | $50-100 |

### What Genomics Adds:

1. **Mechanism identification** - Know WHY it's resistant
2. **Epidemic tracking** - Same gene = outbreak?
3. **Transmission prediction** - Plasmid vs. chromosomal?
4. **New variant detection** - Novel carbapenemases
5. **Treatment optimization** - Target-specific therapy

### Real-World Example: KPC Tracking

**2000**: First KPC-producing *K. pneumoniae* (USA)  
**2005**: Spread to Greece  
**2010**: Global pandemic  
**2015**: Detected in 60+ countries  

**Genomic surveillance** enabled:
- Early outbreak detection
- Transmission route mapping
- Infection control interventions
- Policy changes

**Result**: Contained (but not eliminated)

---

## Learning Goals for This Tutorial

By the end, you will:

‚úÖ Run AMR detection tools (Abricate, AMRFinderPlus)  
‚úÖ Interpret resistance gene results  
‚úÖ Connect genes to antibiotic resistance phenotypes  
‚úÖ Understand clinical treatment implications  
‚úÖ Perform comparative AMR analysis on 48 UPEC genomes  
‚úÖ Generate publication-quality AMR visualizations  
‚úÖ Understand plasmid-mediated resistance mechanisms

Let's begin! üß¨
`,
      estimatedTime: 20
    },
    {
      id: 'amr-tools',
      title: '2. AMR Detection Tools and Databases',
      type: 'text',
      content: `# Tools for AMR Detection

## Three Gold-Standard Tools

### 1. Abricate (Torsten Seemann)

**Strengths**:
- ‚úÖ Fast (seconds per genome)
- ‚úÖ Multiple databases
- ‚úÖ Easy to use
- ‚úÖ BLAST-based (familiar)

**Best For**: Initial screening

\`\`\`bash
abricate --db ncbi genome.fasta
abricate --db resfinder genome.fasta
\`\`\`

---

### 2. NCBI AMRFinderPlus

**Strengths**:
- ‚úÖ Official NCBI tool
- ‚úÖ Curated database
- ‚úÖ Gene + point mutations
- ‚úÖ Species-specific

**Best For**: Comprehensive analysis

\`\`\`bash
amrfinder -n genome.fasta --organism Escherichia
\`\`\`

---

### 3. ResFinder (DTU, Denmark)

**Strengths**:
- ‚úÖ Highly curated
- ‚úÖ Phenotype prediction
- ‚úÖ Web interface available
- ‚úÖ Regularly updated

**Best For**: Clinical reports

---

## AMR Databases

### NCBI AMRFinder Database

**Content**:
- **5,000+ sequences**
- Covers all major resistance classes
- Includes point mutations (gyrA, parC, etc.)
- Updated monthly

**Gene Categories**:
\`\`\`
AMRFinderPlus Database Structure:
‚îú‚îÄ‚îÄ Beta-lactamases
‚îÇ   ‚îú‚îÄ‚îÄ ESBLs (CTX-M, TEM, SHV, etc.)
‚îÇ   ‚îú‚îÄ‚îÄ AmpC (CMY, DHA, etc.)
‚îÇ   ‚îî‚îÄ‚îÄ Carbapenemases (KPC, NDM, OXA, VIM, IMP)
‚îú‚îÄ‚îÄ Aminoglycoside resistance
‚îÇ   ‚îú‚îÄ‚îÄ Acetyltransferases (aac)
‚îÇ   ‚îú‚îÄ‚îÄ Phosphotransferases (aph)
‚îÇ   ‚îî‚îÄ‚îÄ Nucleotidyltransferases (ant)
‚îú‚îÄ‚îÄ Quinolone resistance
‚îÇ   ‚îú‚îÄ‚îÄ qnr genes (qnrA, qnrB, qnrS)
‚îÇ   ‚îú‚îÄ‚îÄ aac(6')-Ib-cr
‚îÇ   ‚îî‚îÄ‚îÄ Point mutations (gyrA, parC)
‚îú‚îÄ‚îÄ Tetracycline resistance
‚îÇ   ‚îî‚îÄ‚îÄ tet genes (tetA, tetB, tetM, etc.)
‚îú‚îÄ‚îÄ Sulfonamide resistance
‚îÇ   ‚îî‚îÄ‚îÄ sul genes (sul1, sul2, sul3)
‚îú‚îÄ‚îÄ Trimethoprim resistance
‚îÇ   ‚îî‚îÄ‚îÄ dfr genes (dfrA, dfrB)
‚îú‚îÄ‚îÄ Macrolide resistance
‚îú‚îÄ‚îÄ Chloramphenicol resistance
‚îú‚îÄ‚îÄ Glycopeptide resistance
‚îî‚îÄ‚îÄ Many others...
\`\`\`

### ResFinder Database

**Content**:
- **3,000+ sequences**
- Highly curated (manual curation)
- Focuses on acquired resistance
- Phenotype prediction

**Antibiotic Classes**:
\`\`\`
- Aminoglycosides
- Beta-lactams
- Colistin
- Fluoroquinolones
- Fosfomycin
- Fusidic acid
- Glycopeptides
- MLS (Macrolides, Lincosamides, Streptogramins)
- Nitroimidazoles
- Oxazolidinones
- Phenicols
- Rifampicin
- Sulphonamides
- Tetracyclines
- Trimethoprim
\`\`\`

### CARD (Comprehensive Antibiotic Resistance Database)

**Content**:
- **6,000+ sequences**
- Includes resistance mechanisms
- Ontology-based organization
- Research-focused

---

## Understanding Database Results

### Typical Abricate Output

\`\`\`
FILE         SEQUENCE  START   END     STRAND  GENE         COVERAGE  IDENTITY  DATABASE
genome.fa    contig_1  12500   13800   +       blaCTX-M-15  100.00    100.00    ncbi
genome.fa    contig_1  45600   46500   +       aac(6')-Ib-cr 100.00   99.78     ncbi
genome.fa    contig_2  5400    6300    -       qnrB1        100.00    100.00    ncbi
\`\`\`

**Column Interpretation**:

- **SEQUENCE**: Which contig contains the gene
- **START/END**: Genomic coordinates
- **STRAND**: + (forward) or - (reverse)
- **GENE**: Resistance gene name
- **COVERAGE**: % of reference gene found (100% = complete gene)
- **IDENTITY**: % sequence similarity (100% = perfect match)
- **DATABASE**: Which database matched

---

### Gene Nomenclature

#### Œ≤-Lactamases

**Format**: `bla` + `Family` + `-` + `Variant`

**Examples**:
- `blaCTX-M-15` = CTX-M family, variant 15
- `blaTEM-1` = TEM family, variant 1
- `blaSHV-12` = SHV family, variant 12
- `blaKPC-2` = KPC family, variant 2
- `blaNDM-1` = NDM family, variant 1
- `blaOXA-48` = OXA family, variant 48

#### Aminoglycoside Resistance

**Format**: `enzyme type` + `(number)` + `-` + `variant`

**Examples**:
- `aac(6')-Ib-cr` = Acetyltransferase, 6' position, variant Ib-cr
- `aph(3')-Ia` = Phosphotransferase, 3' position, variant Ia
- `ant(2")-Ia` = Nucleotidyltransferase, 2" position, variant Ia

**Enzyme types**:
- `aac` = N-Acetyltransferase
- `aph` = O-Phosphotransferase  
- `ant` = O-Nucleotidyltransferase

#### Quinolone Resistance

**Plasmid-mediated**:
- `qnrA`, `qnrB`, `qnrS` = Quinolone resistance proteins
- `aac(6')-Ib-cr` = Dual function (aminoglycoside + quinolone)

**Chromosomal mutations**:
- `gyrA` = DNA gyrase subunit A
- `gyrB` = DNA gyrase subunit B
- `parC` = Topoisomerase IV subunit
- `parE` = Topoisomerase IV subunit

#### Sulfonamide/Trimethoprim Resistance

- `sul1`, `sul2`, `sul3` = Sulfonamide resistance
- `dfrA1`, `dfrA5`, etc. = Dihydrofolate reductase (trimethoprim resistance)

#### Tetracycline Resistance

- `tet(A)` through `tet(Z)` = Efflux pumps or ribosomal protection
- `tet(M)` = Ribosomal protection protein (most common in Gram+)

---

## Quality Metrics

### ‚úÖ High-Confidence Hit

\`\`\`
COVERAGE: 100%
IDENTITY: ‚â•99%
E-value: 0.0
Alignment: No gaps
\`\`\`

**Interpretation**: Gene definitely present

### ‚ö†Ô∏è Medium-Confidence Hit

\`\`\`
COVERAGE: 90-99%
IDENTITY: 95-99%
E-value: <1e-50
Alignment: Minor gaps
\`\`\`

**Interpretation**: Likely present, possibly truncated

### ‚ùå Low-Confidence Hit

\`\`\`
COVERAGE: <90%
IDENTITY: <95%
E-value: >1e-10
Alignment: Many gaps
\`\`\`

**Interpretation**: Possible homolog, not the target gene

---

## Gene-to-Phenotype Mapping

### Example: blaCTX-M-15

**Gene**: `blaCTX-M-15`

**Enzyme**: CTX-M-15 Œ≤-lactamase (ESBL)

**Mechanism**: Hydrolyzes Œ≤-lactam ring

**Phenotype**:
- ‚úÖ Resistant: Ampicillin, amoxicillin
- ‚úÖ Resistant: Cephalosporins (ceftriaxone, cefotaxime, ceftazidime)
- ‚ö†Ô∏è Variable: Cefepime (4th-gen cephalosporin)
- ‚ùå Susceptible: Carbapenems (meropenem, ertapenem)
- ‚ùå Susceptible: Cephamycins (cefoxitin)

**Inhibitors**:
- ‚ö†Ô∏è Partially inhibited by clavulanic acid
- ‚ö†Ô∏è Partially inhibited by tazobactam
- ‚ùå Not inhibited by avibactam (requires BLI combination)

---

### Example: aac(6')-Ib-cr

**Gene**: `aac(6')-Ib-cr`

**Enzyme**: Aminoglycoside acetyltransferase (cr = ciprofloxacin resistance variant)

**Mechanism**: Acetylates aminoglycosides AND quinolones

**Phenotype**:
- ‚úÖ Resistant: Amikacin (moderate)
- ‚úÖ Resistant: Tobramycin
- ‚ö†Ô∏è Variable: Gentamicin (low-level resistance)
- ‚úÖ Resistant: Ciprofloxacin (low-level, but significant)

**Clinical Note**: 
- Often found with blaCTX-M-15 on same plasmid
- Reduces ciprofloxacin effectiveness
- Combined with gyrA mutations ‚Üí high-level fluoroquinolone resistance

---

### Example: qnrB1

**Gene**: `qnrB1`

**Protein**: Quinolone resistance protein

**Mechanism**: Protects DNA gyrase from quinolone binding

**Phenotype**:
- ‚ö†Ô∏è Low-level resistance to fluoroquinolones
- Ciprofloxacin MIC: 0.125 ‚Üí 0.5 Œºg/mL (4-fold increase)
- Often combined with gyrA mutations for high-level resistance

**Clinical Note**:
- Enables bacterial survival during quinolone exposure
- Allows time for chromosomal mutations (gyrA, parC) to emerge
- "Stepping stone" to high-level resistance

---

## Interpretation Guidelines

### Single Gene

\`\`\`
blaCTX-M-15 detected
‚Üí ESBL producer
‚Üí Resistant to 3rd-gen cephalosporins
‚Üí Use carbapenem for severe infections
\`\`\`

### Multiple Co-Located Genes

\`\`\`
blaCTX-M-15 + aac(6')-Ib-cr + qnrB1
‚Üí All on same plasmid (likely)
‚Üí Multidrug-resistant
‚Üí Horizontal transfer risk
‚Üí Outbreak potential
\`\`\`

### Chromosome vs. Plasmid

**Indicators of plasmid-borne resistance**:
- Multiple resistance genes clustered together
- Genes on small contigs (plasmids often assemble separately)
- Presence of plasmid replication genes nearby
- Multiple resistance genes from different classes

**Why it matters**:
- Plasmid genes = highly transmissible
- Chromosome genes = clonal spread only
- Plasmids = infection control priority
`,
      estimatedTime: 20
    }
  ],
  resources: [
    {
      title: 'Abricate - GitHub',
      url: 'https://github.com/tseemann/abricate',
      type: 'tool'
    },
    {
      title: 'NCBI AMRFinderPlus',
      url: 'https://www.ncbi.nlm.nih.gov/pathogens/antimicrobial-resistance/AMRFinder/',
      type: 'tool'
    },
    {
      title: 'ResFinder Database',
      url: 'https://cge.food.dtu.dk/services/ResFinder/',
      type: 'tool'
    },
    {
      title: 'CARD Database',
      url: 'https://card.mcmaster.ca/',
      type: 'tool'
    },
    {
      title: 'WHO AMR Fact Sheet',
      url: 'https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance',
      type: 'article'
    },
    {
      title: 'Aljohani et al. 2023 - UPEC Study',
      url: 'https://doi.org/10.3390/ijms24087582',
      type: 'article'
    }
  ],
  createdAt: '2026-02-13T00:00:00Z',
  updatedAt: '2026-02-13T00:00:00Z'
};
